Evidence map›Paper›PMID 33314759›Full record

ArticleThoracic cancer2021

Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).

Eldsamira Mascarenhas, Ana Caroline Gelatti, Luiz Henrique Araújo, Clarissa Baldotto, Clarissa Mathias, Mauro Zukin, Gustavo Werutsky, Patricia Pacheco, Rafaela Gomes, Gilberto de Castro and 1 more

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Prevalence ofJournal of thoracic disease · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The Clinical and Molecular Profile of Lung Cancer Patients Harboring theInternational journal of molecular sciences · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Identification of theJCO global oncology · 2021
    Article
  18. Frequency ofJCO global oncology · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Eldsamira MascarenhasGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.ORCID 0000-0001-6107-5098
Ana Caroline GelattiGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Luiz Henrique AraújoGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Clarissa BaldottoGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Clarissa MathiasGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Mauro ZukinGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Gustavo WerutskyLatin American Cooperative Oncology Group, Porto Alegre, Brazil.
Patricia PachecoLatin American Cooperative Oncology Group, Porto Alegre, Brazil.ORCID 0000-0002-3330-5869
Rafaela GomesLatin American Cooperative Oncology Group, Porto Alegre, Brazil.
Gilberto de CastroGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Vladmir Cláudio Cordeiro de LimaGrupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil.
Centro Brasileiro de Estudos em Dermatologia · BRAC Camargo Hospital · BRInstituto do Câncer do Estado de São Paulo · BR

Funding

F. Hoffmann-La Roche
6 · The paper itself

Abstract

backgroundThe aim of this study was to carry out a descriptive analysis of the somatic genetic profile and co-occurring mutations of non-small cell lung cancer (NSCLC) samples from patients tested with comprehensive genomic profiling (CGP).

methodsThis was a retrospective cross-sectional study of patients diagnosed with NSCLC from 2013 to 2018 in Brazil and whose samples were submitted to CGP (FoundationOne or FoundationACT) using either tumor or circulating tumor DNA (ctDNA) from plasma.

resultsWe recovered 513 CGP results from patients, 457 (89.1%) of which were from tumors and 56 (10.9%) from plasma. The median age of patients was 64 years old, of which 51.6% were males. TP53 mutations were identified in 53.6% of tumor samples, KRAS mutations in 24.2%, EGFR activating mutations were detected in 22.5%, STK11 mutations in 11.6%, PIK3CA mutations in 8.8%, ALK rearrangements in 5.4%, BRAF mutations in 5.2%, and ERBB2 alterations in 4.9%. The most commonly comutated gene was TP53. TP53 p.R337H was observed in 4.3% of samples and was associated with somatic mutations in EGFR and ERBB2 (P < 0.00001). Tumor mutational burden (TMB) analysis was available for 80.5% of samples tested, and 5.5% of samples had high TMB (≥ 20 mutations/Mb). In conclusion, this retrospective analysis of genomic data from NSCLC patients obtained by CGP showed that common abnormalities such as EGFR mutations and ALK rearrangements had similar frequency to those previously described by other groups using others strategies. Additionally, our data confirm an association between TP53 p.R337H, supposedly germline in nature, and somatic mutations in genes of the HER family. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This is the first report of the prevalence of driver mutations in Brazilian NSCLC patients using comprehensive genomic profiling (CGP). The frequency of the most common driver mutations in this population was similar to that previously described in Brazil. WHAT THIS STUDY ADDS: TP53 was the most commonly comutated gene across samples. TP53 p.R337H was associated with somatic mutations in EGFR and ERBB2. Most samples had low TMB; only 5.5% of samples had high TMB.

Indexed as

AdolescentAdultAgedAged, 80 and overBrazilCarcinoma, Non-Small-Cell LungFemaleGenomicsHumansLung NeoplasmsMaleMiddle AgedMutationRetrospective StudiesYoung AdultCo-occurring mutationsgenomic profilingnon-small cell lung cancertumor mutational burden

Identifiers

PMID33314759
PMCPMC7919136
OpenAlexW3112563534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.